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Abstract
To determine whether Staphylococcus aureus Panton–Valentine leukocidin (PVL) is expressed during human infection, anti-PVL antibody
titres were compared in patients with PVL-positive and PVL-negative staphylococcal infections, and in patients with no evidence of
S. aureus infection. Patients with PVL-positive strains had higher levels of anti-PVL antibodies than individuals of both control groups.
The median anti-PVL titre increased 8.6-fold during the course of PVL-positive infection and 1.4-fold during PVL-negative infection.
These results indicate that only PVL-positive S. aureus strains elicit signiﬁcant anti-PVL antibody production in humans, and demonstrate
the production of PVL during PVL-positive S. aureus infection. The protective role of this immune response remains to be established.
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Introduction
Staphylococcus aureus is an important human pathogen. It
expresses a variety of virulence factors, including Panton–
Valentine leukocidin (PVL) [1]. PVL, together with c-haemol-
ysin and other leukocidins (e.g. LukE, LukD, LukM and LukR),
belongs to the family of synergohymenotropic toxins (SHTs),
which damage host cell and/or erythrocyte membranes by
the synergistic action of two classes of non-associated pro-
teins designated S and F. The F components share 70–80%
sequence identity, and the S components 60–80% sequence
identity [2]. SHTs are antigenically related [3].
Only PVL has been epidemiologically linked to speciﬁc human
S. aureus infections, such as primary skin and soft tissue disease,
severe necrotizing pneumonia, and severe bone and joint infec-
tion [4–6]. These epidemiological links suggest that PVL plays
a role in the pathophysiology of these infections. By using iso-
genic PVL-positive and PVL-negative S. aureus laboratory strains
and recombinant toxins in a mouse model of acute pneumonia,
it was shown that PVL is sufﬁcient to cause pneumonia [7].
However, several groups recently found no differences in
infection severity when isogenic pairs of PVL-positive and
PVL-negative clinical strains were used in mouse models
[8,9]. It is questionable whether or not PVL is actually pro-
duced during human infection. PVL production in vivo could
be indirectly demonstrated on the basis of serological
changes during infection. Some older publications mentioned
anti-PVL antibody production during diseases caused by
S. aureus [10–13], but none speciﬁed whether the strains
produced PVL in vitro. It is therefore difﬁcult to ascertain
whether the anti-PVL antibody responses in these patients
were caused by PVL itself or by antigenically related SHTs.
The aim of this work was to examine anti-PVL antibody
titres in the normal population and in patients with staphylo-
coccal infections due to PVL-negative and PVL-positive strains.
Materials and Methods
Serum specimens
In total, 256 serum samples (from 236 patients) were col-
lected during the year 2002 from three different groups of
immunocompetent patients: (i) patients with no evidence of
S. aureus infection; (ii) patients with documented PVL-positive
S. aureus infections; and (iii) patients with documented PVL-
negative S. aureus infections. One hundred and forty-two
sera were from 142 patients with no evidence of S. aureus
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infection. These patients were divided into 12 age classes as
follows: >0 to £1 year, >1 to £3 years, >3 to £6 years, >6
to £10 years, >10 to £15 years, >15 to £20 years, >20 to
£30 years, >30 to £40 years, >40 to £50 years, >50 to
£60 years, >60 to £70 years, and >70 years. One hundred
and fourteen sera were from S. aureus-infected patients.
Forty-three sera were from 31 patients with documented
PVL-positive S. aureus infections, comprising ten cases of skin
and soft tissue infection, 16 cases of necrotizing pneumonia,
and ﬁve cases of osteomyelitis. Seventy-one sera were from
63 patients with documented PVL-negative S. aureus infec-
tions, comprising 14 cases of skin and soft tissue infection,
one case of Kawasaki disease, three cases of pneumonia, 11
cases of bone and/or joint infection, 16 cases of infective
endocarditis, and 18 cases of bacteraemia. Sera were stored
at )20C until ELISA testing.
S. aureus was identiﬁed on the basis of colony and cell
morphology, coagulase testing with rabbit plasma (bio-
Me´rieux, Marcy l’Etoile, France), and the Staphyslide aggluti-
nation test (bioMe´rieux). Genomic DNA was extracted for
PCR analysis with a standard procedure, and its concentra-
tion was estimated spectrophotometrically. Sequences spe-
ciﬁc for the PVL genes (lukS-PV and lukF-PV, forming the luk-
PV operon) were detected by PCR as previously described
[4].
Human intravenous polyclonal immunoglobulin (IVIg; Te´ge´-
line) was purchased from Laboratoire Franc¸ais du Fractionn-
ement et des Biotechnologies (LBF, Courtaboeuf, France).
Te´ge´line is isolated by fractionation of a pool of IgG col-
lected from 20 000 healthy donors. It contains >97.6% IgG,
composed of IgG1 (58.8%), IgG2 (34.1%), IgG3 (5.4%), and
IgG4 (1.7%), IgA (<1.7%), and traces of pepsin. A standard
range (50, 25, 12.5, 6.25, 3.125, 1.5625 and 0.78125 mg/L)
was prepared from a solution of Te´ge´line (50 g/L) and used
for antibody detection in clinical samples. Te´ge´line contains
PVL-speciﬁc antibodies (against LukS-PV and LukF-PV) as
shown by ELISA [14].
Anti-LukS-PV and anti-LukF-PV immunoassays
Recombinant LukS-PV and LukF-PV (rLukS-PV and rLukF-PV)
were puriﬁed from Escherichia coli culture supernatants as
previously described [15]. Anti-LukS-PV and anti-LukF-PV
antibodies were detected in IVIg and sera by using a speciﬁc
ELISA method with solid-phase rLukS-PV and rLukF-PV and
peroxidase-conjugated anti-immunoglobulin antibodies. The
procedure was adapted from current protocols in molecular
biology [16]. The wells of microtitre plates (Sigma, Saint
Quentin Fallavier, France) were coated with 125 mg/L of
rLukS-PV and rLukF-PV in phosphate-buffered saline over-
night at room temperature, and this was followed by incuba-
tion with a blocking solution of phosphate-buffered saline–
Tween (0.05%) containing lyophilized skimmed milk (10 g/L)
for 30 min at 37C.
Unbound rLukS and rLukF was washed out twice with the
blocking solution. Serial dilutions of IVIg (50–0.78 mg/L) (for
the standard range) and sera (diluted 1 : 1000–1 : 100 000)
were added to duplicate wells for 1 h at 37C, and then per-
oxidase-conjugated rabbit anti-human polyvalent IgG (diluted
1 : 30 000) (Sigma) was added after three washes. The mi-
croplates were incubated for 1 h at 37C, and washed
before addition of the substrate tetramethylbenzidine
(Sigma). The reaction was stopped with 75 ll of 1 M H2SO4.
The plates were read at 450 nm in a Model 680 micro-
plate reader (BioRad, Marnes-la-Coquette, France). The stan-
dard curve was linear with an r2 value of 0.99.
The results were expressed in arbitrary units per litre
(AU/L); 1000 arbitrary units correspond to the amount of
anti-PVL antibodies contained in a solution of commercial
human polyclonal immunoglobulins at 12.5 g/L, which is the
physiological human immunoglobulin serum concentration.
Statistical analysis
The Mann–Whitney U-test was implemented with SPSS soft-
ware version 11.0 (SPSS Inc., Chicago, IL, USA) and used to
identify differences in anti-PVL titres between groups of sera.
The level of statistical signiﬁcance was set at p < 0.05.
Results
Distribution of PVL antibody levels in patients with no evi-
dence of S. aureus infection
Anti-PVL antibody levels in individuals free of S. aureus infec-
tion ranged from 102 to 15 681 AU/L (median 854 AU/L),
and were distributed in log normal mode with an additional
small peak at 7000–9000 (Fig. 1). Antibody levels were low
in the ﬁrst three age groups (0–1 year, 1–3 years, and 3–
6 years; median 382 AU/L), and signiﬁcantly increased in the
next two age groups of 6–10 years and 10–15 years (median
1502 and 1930 AU/L, respectively; p <0.001) (Fig. 2). In indi-
viduals between 15 and 40 years of age, the anti-PVL level
was lower than in the previous two age groups (median
789 AU/L), and then increased slightly with age until
70 years.
Distribution of PVL antibody levels in infected patients
Anti-PVL antibody titres in the initial serum samples of
patients with PVL-negative S. aureus infection ranged from 40
to 47 645 AU/L (median 1300 AU/L) and were not signiﬁ-
cantly different from the control values. Titres in patients
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with PVL-positive S. aureus infection ranged from 200 to
400 000 AU/L (median 10 070 AU/L) and were signiﬁcantly
higher than the titres in patients with no evidence of
S. aureus infection and patients with PVL-negative S. aureus
infection (p <0.001) (Fig. 3). For patients with PVL-positive
S. aureus infection, anti-PVL titres were not signiﬁcantly dif-
ferent among those with skin and soft tissue infections, nec-
rotizing pneumonia or osteomyelitis.
Serial samples
Paired serum samples were available for 12 patients infected
with PVL-producing S. aureus strains and eight patients
infected with PVL-negative S. aureus strains. The interval
between the two samples ranged from 3 to 210 days, and
was not signiﬁcantly different between the two groups of
patients (p 0.70).
The median anti-PVL titre in patients with PVL-producing
strains increased from 15 540 in the ﬁrst sample to
64 953 AU/L in the second sample (range 4609–33 571 and
21 377–125 852 AU/L, respectively) from patients with skin
and soft tissue infections, and from 2254 to 46 850 AU/L
FIG. 1. Distribution of anti-Panton–Valentine leukocidin (PVL) anti-
body levels in patients with no evidence of Staphylococcus aureus
infection.
FIG. 2. Distribution of anti-Panton–Valentine leukocidin (PVL) anti-
body levels in the different age groups of patients with no evidence
of Staphylococcus aureus infection. Bars show median values.
FIG. 3. Distribution of anti-Panton–Valentine leukocidin (PVL) anti-
body levels in the three populations studied: 142 sera from patients
with no evidence of Staphylococcus aureus infection (S0); 71 sera from
patients with PVL-negative S. aureus infection, comprising 63 ﬁrst
sera (S1) and 8 second sera (S2); and 43 sera from patients with
PVL-positive S. aureus infection, comprising 31 ﬁrst sera (S1) and 12
second sera (S2). Bars show median values.
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(range 387–14 336 and 859–400 000 AU/L, respectively) in
the respective samples from patients with necrotizing pneu-
monia. In patients with PVL-negative S. aureus infection, med-
ian anti-PVL titres increased from 2516 to 3302 AU/L (range
1203–3940 and 2198–4187 AU/L, respectively).
The titre in the second sample was almost always higher
than that in the ﬁrst. The ratio of anti-PVL titres of the two
samples was signiﬁcantly higher in patients with PVL-produc-
ing S. aureus strains (median 8.6; 4.6 in the case of skin and
soft tissue infections and 10.4 in that of necrotizing pneumo-
nia) than in patients with PVL-negative S. aureus strains (med-
ian 1.4; p 0.002). The only exception was the single patient
who died of necrotizing pneumonia and whose anti-PVL titre
fell from 3275 to 859 AU/L.
Discussion
The results of this study clearly show that only S. aureus
strains harbouring the luk-PV genes elicit signiﬁcant anti-PVL
antibody production in humans. Patients with strains harbour-
ing luk-PV genes had higher levels of anti-PVL antibodies than
individuals with no evidence of S. aureus infection. Moreover,
the median anti-PVL level increased 8.6-fold during the
course of PVL-positive S. aureus infection (12 patients) and
only 1.4-fold in patients with PVL-negative S. aureus infection
(eight patients). The observed rise in the anti-PVL antibody
titre indirectly conﬁrms that PVL is produced during human
infection. Direct evidence for this production has been pro-
vided by PVL detection in pus from patients with skin infec-
tions [17]. Altogether, this suggests that PVL may contribute
to the pathophysiology of human S. aureus infection.
Strong responses to PVL were observed in most patients
with PVL-positive infections, with three exceptions. In a
patient with recurrent furunculosis, the initial anti-PVL anti-
body titre was already very high (33 571 AU/L), and
increased only to 64 953 AU/L; in the only fatal case of nec-
rotizing pneumonia of this survey, the initial anti-PVL titre
was 3275 AU/L (i.e. normal for the age), and it fell four-fold
3 days before death. The speciﬁc antibodies may have been
consumed by PVL in this patient. In another case of necrotiz-
ing pneumonia, the patient relapsed 20 days after the ﬁrst
episode. The anti-PVL antibody titre increased only from 520
to 981 AU/L during this period. As anti-PVL antibodies can
neutralize PVL activity [14], it is tempting to speculate that
the weak immune response to PVL in these two patients
could have negatively affected their outcome. A signiﬁcant
increase in the anti-PVL titre may favourably inﬂuence clinical
outcome [10,13,18]. Johanovsky [18] observed a negative
correlation between the severity of human S. aureus infection
and the anti-leukocidin titre. Panton and Valentine also sug-
gested in 1932 that ‘anti-leukocidin antisera or vaccine could
be a useful therapeutic approach for serious PVL-producing
S. aureus strains infections which did not respond well to
available treatment’ [10].
In 1965, Mudd et al. [19] tested PVL toxoid injection as an
adjunctive treatment for disease caused by S. aureus, and
observed an increase in anti-PVL titres and a beneﬁcial effect
in patients with osteomyelitis and soft tissue infection.
Another question concerns host susceptibility to PVL and
the possible link between absence of protective antibodies
and outcome of PVL-positive infection. However, in this
study, patients with PVL-positive infection had higher anti-
PVL antibody titres than patients with PVL-negative infection.
As anti-PVL antibodies neutralize PVL activity, and most of
the patients developed strong immune responses to PVL, we
suspect that the immune response was already underway
when the ﬁrst samples were obtained, making it impossible
for us to address this question.
In subjects with no evidence of S. aureus infection, there
was a particular age distribution of anti-PVL titres. As
expected, levels of anti-PVL antibodies increased gradually
with age, but a peak between 6 and 15 years was observed.
No such peak has been observed with other S. aureus anti-
gens, e.g. whole bacteria, cell wall teichoic acid, peptidogly-
can, and exfoliative toxins. Anti-S. aureus antibody titres
usually increase continuously until adolescence, and then
level off [20–23]. It will be interesting to conﬁrm this partic-
ular age distribution of anti-PVL in a larger population and to
determine whether it correlates with age of colonization or
infection by PVL-positive S. aureus.
In conclusion, the results of this study clearly show that
only strains harbouring luk-PV genes can elicit signiﬁcant anti-
PVL antibody production in humans, indirectly conﬁrming
PVL production during human infection. The protective role
of this immune response remains to be determined.
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